Anti-microbial/Anti-fungal Tests Market is predicted to expand at a CAGR rate of 5.7% by 2032

Microbial and fungal infections are a major cause of death globally and can even cause potential epidemics, creating a huge economic burden on countries, especially developing ones. To nip the spread of such infections in the bud, prevention is a far better solution than cure – accomplished by isolating infected cases and carrying out primary screening tests. By the end of 2022, the market for anti-microbial/anti-fungal diagnostics is anticipated to be worth US$2.5 billion. By 2032, it is expected that market growth would exceed US$ 4.5 billion at a CAGR of 5.7%. With a market share of roughly 53.5% in 2021, molecular-based tests held the top spot according to test type. global anti-microbial/ anti-fungal tests market for a decade.

Region – Robust Healthcare Infrastructure in North America Enables Rapid Anti-Microbial/ Anti-Fungal Testing

North America has the largest regional contribution and is predicted to account for approx. a third of the anti-microbial/ anti-fungal tests market at the end of the forecast period. The North America anti-microbial/ anti-fungal tests market should cross a billion dollars by 2027 – the only region to do so. Most physicians on the continent typically prescribe diagnostics tests before starting any sort of treatment, fuelling demand for anti-microbial/ anti-fungal test kits. Furthermore, there is immense awareness of the side-effects of certain drugs and patients often prefer to get completely diagnosed before seeking treatment.

To remain ‘ahead’ of your competitors, request for a sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-5566

Test Type – Molecular Based Tests Critical in Anti-Microbial/ Anti-Fungal Tests Market

Molecular based tests dominated the global anti-microbial/ anti-fungal tests market by test type in 2017 and are likely to retain this commanding position for the foreseeable future. Molecular based tests have a market attractiveness index of 2.6 – considerably higher than all other test types in the anti-microbial/ anti-fungal tests market. Within the molecular based tests segment, companies would be advised to focus their attention on the PCR Test sub-segment as it is roughly thrice the size of DNA microarray tests in terms of value. The PCR test segment is further poised to record a CAGR of 6.4% for the decadal study.

Infection Type – Target Antimicrobial Resistance and Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market

The antimicrobial and microbial resistance segments are the ones to look out for as they comprise almost 3/4^th of the global anti-microbial/ anti-fungal tests market between them. The multi-drug-resistant mycobacterium tuberculosis sub-segment is the largest in the antimicrobial resistance segment and should grow at a high rate as well. Along with multi-drug-resistant mycobacterium tuberculosis, the microbial infection segment holds great potential in the anti-microbial/ anti-fungal tests market as it is on track to push past a value of US$ 1 billion by end 2027.

For insights on global, regional, and country-level parameters with growth opportunities from 2022 to 2032, Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-5566

End User – Hospitals and Reference Labs Demand Antimicrobial/ Antifungal Testing Kits

Hospitals and reference labs are the largest end users in the anti-microbial/ anti-fungal tests market by a substantial margin. It has been observed that the global per-capita healthcare spending has doubled because of rising awareness of myriad treatment options and diagnostic tools for detecting and curing various diseases. Reference labs are predicted to grow faster than hospitals in the anti-microbial/ anti-fungal tests market.

Competition Dashboard in the Anti-Microbial/ Anti-Fungal Tests Market

The companies profiled in the report are Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories, Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience, Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc.

Takeaways

The prevalence and incidence rate of infectious diseases such as diarrhoea and malaria is at an all-time high in Asia and Africa. Governmental and non-governmental organizations such as the WHO are seeking to reduce prevalence rates by early diagnosis through antimicrobial and antifungal kits. In addition to this, government tenders and partnerships with manufacturers is anticipated to provide a steady revenue stream for the latter, growing the  anti-microbial/ anti-fungal tests market as a whole.

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-5566

Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research

By Tests Type:

• Molecular Based Tests
  • PCR Test
  • DNA Microarray
• Phenotypic Resistance Tests
• Complex Test Panels
• Mass Spectrometry
• Rapid Diagnostic Tests
  • E-Test Antibiotic/Antifungal Strips
  • Biosensor Platforms

By Infection Type:

• Antimicrobial Resistance
  • Methicillin-Resistant Staphylococcus Aureus
  • Vancomycin-Resistant Enterococcus
  • Multi-Drug-Resistant Mycobacterium tuberculosis
  • Carbapenem-Resistant Enterobacteriaceae gut bacteria
• Microbial Infection
• Antifungal Resistance
  • Candida infections
  • Aspergillus infection
  • Fusariosis
  • Others
• Fungal Infection

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Community Health Centers
• Reference Laboratories

About Us

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs